CG Oncology (CGON) Change in Receivables (2024 - 2026)
CG Oncology's (CGON) quarterly Change in Receivables came in at $587000.0 in Q1 2026, up 234.63% YoY from $175416.0 in Q1 2025, and up 95.02% on a QoQ basis from $301000.0 in Q4 2025.
CG Oncology (CGON) Change in Receivables (2024 - 2026) Analysis & Trends
CG Oncology (CGON) has 3 years of Change in Receivables data on file, last reported at $587000.0 in Q1 2026.
- Quarterly Change in Receivables rose 234.63% year-over-year to $587000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (changed N/A YoY) and the FY2025 annual result came in at $320000.0, down 53.56% from the prior year.
- Change in Receivables improved to $587000.0 in Q1 2026, from $301000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $644000.0 in Q4 2024 to a low of -$436000.0 in Q1 2025.
- A 3-year average of $215142.9 and a median of $238000.0 in 2025 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 628.89% in 2025, down 53.26% in 2025.
- Tracing CGON's Change in Receivables over 3 years: stood at $644000.0 in 2024, then plunged by 53.26% to $301000.0 in 2025, then jumped by 95.02% to $587000.0 in 2026.
- The last three Change in Receivables figures came in at $587000.0 (Q1 2026), $301000.0 (Q4 2025), and $238000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | -858,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -858,000.00 |
| Jun 30, 2026 | -858,000.00 |
| Mar 31, 2026 | 587,000.00 |
| Mar 31, 2026 | 587,000.00 |
| Dec 31, 2025 | 301,000.00 |
| Dec 31, 2025 | 301,000.00 |
| Sep 30, 2025 | 238,000.00 |
| Sep 30, 2025 | 238,000.00 |
| Jun 30, 2025 | 217,000.00 |
| Jun 30, 2025 | 217,000.00 |
| Mar 31, 2025 | -436,000.00 |
| Mar 31, 2025 | -436,000.00 |
| Dec 31, 2024 | 644,000.00 |
| Dec 31, 2024 | 644,000.00 |
| Sep 30, 2024 | -45,000.00 |
| Sep 30, 2024 | -45,000.00 |